EUVIMEDEUVIMED entdecken
Crossref

Development and evaluation of a virus-like particle PEDV vaccine based on MS2 bacteriophage

Yawen Liu, Siying Du, Shan Xu, Yigang Tong

European Journal of Pharmaceutics and Biopharmaceutics · 2026

DOI: 10.1016/j.ejpb.2026.115221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Yawen Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: BAICSM, State Key Laboratory of Green Biomanufacturing, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 10…. Hauptthemen laut MEDLINE: Porcine epidemic diarrhea virus, Viral Vaccines, Vaccines, Virus-Like Particle, Levivirus. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Porcine epidemic diarrhea virus (PEDV) can infect pigs of all ages, causing porcine epidemic diarrhea and resulting in significant losses to the global pig farming industry. The virus causes epidemic diarrhea and represents a significant threat to the global swine industry. To enhance vaccine safety and protective efficacy, a PEDV nanoparticle vaccine (PEDV-MS2 VLP) based on MS2 bacteriophages was developed. The MS2 phage coat (MS2 VLP) self-assembles into nanoparticles within Escherichia coli. It is conjugated to the PEDV RBD antigen via the SpyTag-SpyCatcher system, forming a structure mimicking the natural virus. Subcutaneous immunization of BALB/c mice with PEDV-MS2 VLP at days 0 and 14 resulted in a 100-fold increase in neutralizing titers and robust antigen-specific IgG responses. Additionally, PEDV-MS2 VLP induced high levels of cytokines (TNF-α, IFN-γ). The vaccine showed no significant toxicity to the liver, kidneys, or heart in mice. In summary, PEDV-MS2 VLPs demonstrate excellent safety and are a novel candidate vaccine for porcine epidemic diarrhea virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Porcine epidemic diarrhea virusViral VaccinesVaccines, Virus-Like ParticleLevivirusCoronavirus InfectionsAnimalsMice, Inbred BALB CMiceAntibodies, ViralFemaleSwineCytokinesNanoparticlesNanovaccinesImmunoglobulin G

Substanzen

Viral VaccinesVaccines, Virus-Like ParticleAntibodies, ViralCytokinesNanovaccinesImmunoglobulin G

Autor:innen und Institutionen

  • BAICSM, State Key Laboratory of Green Biomanufacturing, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
  • BAICSM, State Key Laboratory of Green Biomanufacturing, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. Electronic address: shanxu@buct.edu.cn.
  • BAICSM, State Key Laboratory of Green Biomanufacturing, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. Electronic address: tongyigang@mail.buct.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, Y., Du, S., Xu, S., & Tong, Y. (2026). Development and evaluation of a virus-like particle PEDV vaccine based on MS2 bacteriophage. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115221

Vancouver

Liu Y, Du S, Xu S, Tong Y. Development and evaluation of a virus-like particle PEDV vaccine based on MS2 bacteriophage. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115221

BibTeX
@article{Liu2026,
  author = {Liu, Yawen and Du, Siying and Xu, Shan and Tong, Yigang},
  title = {Development and evaluation of a virus-like particle PEDV vaccine based on MS2 bacteriophage},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  doi = {10.1016/j.ejpb.2026.115221}
}
Kostenlos starten →